Global Variation in Clinical Profile, Management, and Post-Discharge Outcomes Among Patients Hospitalized For Worsening Chronic Heart Failure: Findings from the ASTRONAUT trial
Authors:
- Gregg C FonarowGFGregg C Fonarow
- Aldo P MaggioniAldo P Maggioni
- Mihai GheorghiadeMGMihai Gheorghiade
- ASTRONAUT Investigators and CoordinatorsACASTRONAUT Investigators and Coordinators
- 30 April 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 17 (6) , 591-600
Abstract
Aims This study sought to investigate regional variation in clinical characteristics, therapy utilization, and post‐discharge outcomes among patients hospitalized for heart failure (HHF) enrolled in the multinational ASTRONAUT (Aliskiren Trial on Acute Heart Failure Outcomes) trial. Methods and results The ASTRONAUT trial randomized 1615 HHF patients with ejection fraction ≤40% to aliskiren or placebo. Enrolled patients were from Eastern Europe (n = 495, 30.7%), Asia/Pacific (n = 439, 27.2%), Western Europe (n = 395, 24.5%), Latin America (n = 163, 10.1%), and North America (n = 123, 7.6%). Marked differences were seen across geographic regions in terms of baseline demographics, vital signs, laboratory tests, co‐morbidity burden, and use of guideline‐recommended therapies. All‐cause death at 12 months ranged from 7.3% in North America to 26.7% in Asia/Pacific, with differences largely driven by sudden cardiac death. Rates of repeat HHF at 12 months ranged from 22.7% in Latin America to 43.9% in North America. After adjustment for patient characteristics, region was an independent predictor of death at 12 months, with highest risk in Asia/Pacific (hazard ratio 3.04, 95% confidence interval 1.47–6.29, compared with North America) and lowest risk in North America and Western Europe. There was no association between region and the composite of cardiovascular mortality or HHF. Conclusion For patients enrolled in this HHF trial, baseline characteristics and risk of death differed markedly by geographic region. Rates of death and repeat HHF demonstrated a general inverse relationship. Global differences in patient characteristics and outcomes should be accounted for when designing future HHF clinical trials.Keywords
This publication has 28 references indexed in Scilit:
- Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?Circulation: Heart Failure, 2013
- Relationship Between Hospital Readmission and Mortality Rates for Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, or PneumoniaJAMA, 2013
- The disconnect between phase II and phase III trials of drugs for heart failureNature Reviews Cardiology, 2013
- Patient Characteristics From a Regional Multicenter Database of Acute Decompensated Heart Failure in Asia Pacific (ADHERE International–Asia Pacific)Journal of Cardiac Failure, 2012
- Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term OutcomesCirculation: Heart Failure, 2011
- Effect of Nesiritide in Patients with Acute Decompensated Heart FailureNew England Journal of Medicine, 2011
- Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart FailureNew England Journal of Medicine, 2010
- Implantable Cardioverter-Defibrillators in Patients Hospitalized for Heart Failure With Chronically Reduced Left Ventricular Ejection FractionAmerican Journal of Therapeutics, 2010
- Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart FailureJACC, 2008
- Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)American Heart Journal, 2008